For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates for patients with breast cancer.
The Oncology Institute
Latest Content
Treatment with the investigational Bruton’s tyrosine kinase inhibitor, pirtobrutinib, will be compared with ibrutinib treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in a phase 2 study.
A publicly traded leader in value-based oncology care raises standards in patient safety.
An executive announcement from the Oncology of Hope and Innovation Institute.
Two new TOI-affiliated oncology practices have open in South Florida.
The Oncology InstituteeExpands board to 9 members with deep healthcare management and investment experience.
The Oncology Institute, Inc ave partnered to provide enhanced psychological support services for TOI patients.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5
